Form4insider filings, from the source

SEC Form 4 · accession 0000919574-17-006672

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
ARMISTICE CAPITAL, LLC
Director · 10% Owner
Steven Boyd
10% Owner
Period of report
Sep 6, 2017
Accepted (ET)
Sep 8, 2017 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Sep 6, 2017P2,239$0.7358A15,911,076D
Common StockF2Sep 6, 2017P$00$0.00A15,911,076ISee Footnote
Common StockF2Sep 6, 2017P$00$0.00A15,911,076ISee Footnote
Common StockF1Sep 8, 2017P2,060$0.7531A15,913,136D
Common StockF2Sep 8, 2017P$00$0.00A15,913,136ISee Footnote
Common StockF2Sep 8, 2017P$00$0.00A15,913,136ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
WarrantsF1,F3$0.40holding————Jun 30, 2022Common Stock14,285,71414,285,714D
WarrantsF2,F3$0.40holding————Jun 30, 2022Common Stock14,285,71414,285,714I
WarrantsF2,F3$0.40holding————Jun 30, 2022Common Stock14,285,71414,285,714I

Explanation of responses